James M. Rusnak

1.8k total citations · 1 hit paper
27 papers, 1.3k citations indexed

About

James M. Rusnak is a scholar working on Molecular Biology, Infectious Diseases and Epidemiology. According to data from OpenAlex, James M. Rusnak has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 8 papers in Infectious Diseases and 4 papers in Epidemiology. Recurrent topics in James M. Rusnak's work include COVID-19 Clinical Research Studies (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Respiratory viral infections research (3 papers). James M. Rusnak is often cited by papers focused on COVID-19 Clinical Research Studies (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers) and Respiratory viral infections research (3 papers). James M. Rusnak collaborates with scholars based in United States, Mexico and Poland. James M. Rusnak's co-authors include John S. Lazo, Daniel R. Lucey, Dale G. Hoyt, Bruce R. Pitt, John B. Kostis, Jonathan Corren, Thomas B. Casale, Allen P. Kaplan, Elliott Levy and Yukihiro Kondo and has published in prestigious journals such as New England Journal of Medicine, Biochemistry and Clinical Infectious Diseases.

In The Last Decade

James M. Rusnak

27 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19

2024 50 citations Jennifer Hammond, Robert J. Fountaine et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James M. Rusnak United States	19	493	193	182	154	150	27	1.3k
Juleen A. Cavanaugh Australia	19	564 1.1×	208 1.1×	186 1.0×	123 0.8×	89 0.6×	44	1.9k
Jennifer Lin United States	17	496 1.0×	215 1.1×	77 0.4×	363 2.4×	103 0.7×	43	1.6k
Masaaki Korenaga Japan	24	418 0.8×	118 0.6×	121 0.7×	129 0.8×	66 0.4×	79	2.4k
Michiari Okuda Japan	15	355 0.7×	132 0.7×	115 0.6×	107 0.7×	67 0.4×	28	1.9k
Satoshi Funakoshi Japan	22	739 1.5×	76 0.4×	110 0.6×	206 1.3×	40 0.3×	72	1.6k
Eugene O. Apostolov United States	23	480 1.0×	95 0.5×	46 0.3×	74 0.5×	30 0.2×	33	1.4k
Stefania Marsico Italy	22	628 1.3×	126 0.7×	60 0.3×	554 3.6×	109 0.7×	55	2.0k
Samuel E. Adunyah United States	25	681 1.4×	52 0.3×	73 0.4×	368 2.4×	39 0.3×	66	1.5k
N R Chowdhury United States	22	1.1k 2.3×	46 0.2×	78 0.4×	213 1.4×	116 0.8×	38	2.1k
Daniel Rost Germany	19	302 0.6×	219 1.1×	158 0.9×	822 5.3×	144 1.0×	29	1.7k

Countries citing papers authored by James M. Rusnak

Since Specialization

Citations

This map shows the geographic impact of James M. Rusnak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Rusnak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Rusnak more than expected).

Fields of papers citing papers by James M. Rusnak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Rusnak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Rusnak. The network helps show where James M. Rusnak may publish in the future.

Co-authorship network of co-authors of James M. Rusnak

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Rusnak. A scholar is included among the top collaborators of James M. Rusnak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Rusnak. James M. Rusnak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weinstein, Edward A., Roger Paredes, Annie Gardner, et al.. (2025). Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial. The Lancet Infectious Diseases. 25(11). 1243–1253. 3 indexed citations

Hammond, Jennifer, Robert J. Fountaine, Carla Yunis, et al.. (2024). Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. New England Journal of Medicine. 390(13). 1186–1195. 50 indexed citations breakdown →

Hammond, Jennifer, Carla Yunis, Robert J. Fountaine, et al.. (2024). Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine. 391(3). 224–234. 6 indexed citations

Bao, Weihang, Robert J. Fountaine, Mary Lynn Baniecki, et al.. (2023). 532. Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients. Open Forum Infectious Diseases. 10(Supplement_2). 5 indexed citations

Ford, Emily S., William Simmons, Ellora Karmarkar, et al.. (2022). Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir. Clinical Infectious Diseases. 76(5). 926–929. 40 indexed citations

Hammond, Jennifer, Annie Gardner, Paula Abreu, et al.. (2022). 786. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits. Open Forum Infectious Diseases. 9(Supplement_2). 6 indexed citations

Amin, Neeta B., et al.. (2015). Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obesity and Metabolism. 17(6). 591–598. 57 indexed citations

Kostis, John B., James M. Rusnak, Thomas B. Casale, et al.. (2005). Incidence and Characteristics of Angioedema Associated With Enalapril. Archives of Internal Medicine. 165(14). 1637–1637. 218 indexed citations

Rusnak, James M., et al.. (2001). Pharmacogenomics: A Clinician's Primer on Emerging Technologies for Improved Patient Care. Mayo Clinic Proceedings. 76(3). 299–309. 48 indexed citations

10.

Rusnak, James M., Stephen L. Kopecky, Ian P. Clements, et al.. (2001). An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). The American Journal of Cardiology. 88(5). 482–487. 56 indexed citations

11.

Bredel, Markus, Ian F. Pollack, John Freund, James M. Rusnak, & John S. Lazo. (1999). Protein Kinase C Inhibition by UCN-01 Induces Apoptosis in Human Glioma Cells in a Time-dependent Fashion. Journal of Neuro-Oncology. 41(1). 9–20. 18 indexed citations

12.

Kondo, Yukihiro, et al.. (1997). Enhanced Apoptosis in Metallothionein Null Cells. Molecular Pharmacology. 52(2). 195–201. 148 indexed citations

13.

Rice, Robert, James M. Rusnak, Fumiaki Yokokawa, et al.. (1997). A Targeted Library of Small-Molecule, Tyrosine, and Dual-Specificity Phosphatase Inhibitors Derived from a Rational Core Design and Random Side Chain Variation. Biochemistry. 36(50). 15965–15974. 78 indexed citations

14.

Rusnak, James M. & John S. Lazo. (1996). Downregulation of Protein Kinase C Suppresses Induction of Apoptosis in Human Prostatic Carcinoma Cells. Experimental Cell Research. 224(1). 189–199. 36 indexed citations

15.

Rusnak, James M., Thierry Calmels, Dale G. Hoyt, et al.. (1996). Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells.. Molecular Pharmacology. 49(2). 244–252. 28 indexed citations

16.

Wong, Hector R., Robert Mannix, James M. Rusnak, et al.. (1996). The Heat-Shock Response Attenuates Lipopolysaccharide-Mediated Apoptosis in Cultured Sheep Pulmonary Artery Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology. 15(6). 745–751. 66 indexed citations

17.

Wipf, Peter, Wenjie Li, Christianah Moji Adeyeye, James M. Rusnak, & John S. Lazo. (1996). Synthesis of chemoreversible prodrugs of ara-C with variable time-release profiles. Biological evaluation of their apoptotic activity. Bioorganic & Medicinal Chemistry. 4(10). 1585–1596. 25 indexed citations

18.

Hoyt, Dale G., James M. Rusnak, Robert Mannix, et al.. (1996). Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells.. PubMed. 56(18). 4146–9. 45 indexed citations

19.

Ritke, M K, James M. Rusnak, J S Lazo, et al.. (1994). Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells.. Molecular Pharmacology. 46(4). 605–611. 54 indexed citations

20.

Kozikowski, Alan P., Abdul H. Fauq, & James M. Rusnak. (1989). A simplified route to the phosphatidylinositol cascade inhibitor --- (-)-1L-1-deoxy-1-fluoro-Myo-inositol. Tetrahedron Letters. 30(26). 3365–3368. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact